The largest database of trusted experimental protocols
> Procedures > Therapeutic or Preventive Procedure > Cardiac Resynchronization Therapy

Cardiac Resynchronization Therapy

Cardiac Resynchronization Therapy (CRT) is a therapeutic approach used to treat heart failure patients with electrical conduction delays.
CRT involves implanting a specialized pacemaker device that coordinates the contractions of the heart's lower chambers (ventricles), improving the efficiency of the pumping action.
This therapy can help alleviate symptoms, enhance quality of life, and reduce the risk of hospitalization for individuals with certain types of heart failure.
PubCompare.ai's AI-driven platform enables researchers to easily locate the best CRT research protocols from the literature, preprints, and patents, facilitating reproducibility and accuracy in their investigations.
Expereince the future of protocol optimization today with PubCompare.ai's cutting-edge tools.

Most cited protocols related to «Cardiac Resynchronization Therapy»

In comparing the survival distributions of two or more groups (for example, new therapy vs standard of care), Kaplan-Meier estimation1 and the log-rank test2 are the basic statistical methods of analyses. These are non-parametric methods in that no mathematical form of the survival distributions is assumed. If an investigator is interested in quantifying or investigating the effects of known covariates (e.g., age or race) or predictor variables (e.g., blood pressure), regression models are utilized. As in the conventional linear regression models, survival regression models allow for the quantification of the effect on survival of a set of predictors, the interaction of two predictors, or the effect of a new predictor above and beyond other covariates.
Among the available survival regression models, the Cox proportional hazards model developed by Sir David Cox3 has seen great use in epidemiological and medical studies, and the field of nuclear cardiology is no exception. What follows are some examples of Cox models being used in nuclear cardiology. Xu et al4 (link) looked at how myocardial scarring (assessed with positron emission tomography [PET] or single photon emission computed tomography [SPECT]) and other demographic and medical history factors predicted mortality in patients with advanced heart failure who received cardiac resynchronization therapy. Bourque et al5 (link) looked at how left ventricular ejection fraction (LVEF, assessed with angiography) and nuclear summed rest score (SRS, assessed with SPECT) interacted to change the risk of mortality. Hachamovitch and Berman6 (link) looked at the incremental prognostic value of myocardial perfusion SPECT (MPS) parameters in the prediction of sudden cardiac death. Nakata et al7 (link) looked at how the heart-to-mediastinum ratio (assessed with metaiodobenzylguanidine [MIBG] imaging) predicted cardiac death.
Survival models other than the Cox model have been used in nuclear cardiology as well. For example, in a study of diagnosis strategies for quantifying myocardial perfusion with SPECT, Duvall et al8 (link) utilized a log-normal survival model, a member of the parametric family of regression survival models, since initial data exploration revealed that the proportional hazards assumption of the Cox model was invalid. While this is an excellent example of when to utilize other survival models, it has been more common to see such data presented in conjunction with a Cox model analysis. In earlier studies of MPS-derived predictors of cardiac events, Hachamovitch et al9 (link) used Cox models to identify significant predictors and parametric models, specifically the accelerated failure time (AFT) model, to make estimates of the time to certain percentiles of survival. An identical analysis strategy was used by the research group comprised of Cuocolo, Acampa, Petretta, Daniele et al10 (link)–13 (link) in their research of the impact of various SPECT-derived predictors on the occurrence of cardiac events.
Publication 2014
3-Iodobenzylguanidine Angiography Blood Pressure Cardiac Death Cardiac Events Cardiac Resynchronization Therapy Cardiovascular System Family Member Heart Heart Failure Mediastinum Myocardium Patients Perfusion Positron-Emission Tomography Sudden Cardiac Death Tests, Diagnostic Therapeutics Tomography, Emission-Computed, Single-Photon Ventricular Ejection Fraction
The RACE V is an investigator-initiated, prospective, multicentre registry aiming to include 750 patients in multiple centres in The Netherlands. A total of 202 patients were included in five centres for the current interim analysis between June 2016 and December 2017. Inclusion criteria included patients aged >18 years with paroxysmal AF; a maximum history of 10 years since diagnosis at the moment of inclusion; a maximum CHA2DS2-VASc score of 5; and no other indication for anticoagulation drugs (e.g. mechanical valve prosthesis). Patients had to have at least two documented episodes of paroxysmal AF in the past year or one documented episode combined with at least two symptomatic episodes in the past year suspected to be AF. In patients with a Medtronic Advisa® pacemaker, atrial high rate episodes (AHRE) >190 beats per minute lasting >6 min were qualified as AF episodes. Patients with other types of pacemakers, defibrillators, or cardiac resynchronization therapy could not participate due to differences in AHRE algorithm or incompatibility with the type of home-monitoring. Patients with a history of persistent AF, currently treated with amiodarone, current pregnancy, or a life expectancy <2.5 years were not eligible to participate. Patients with AF caused exclusively by transient triggers (e.g. post-operative, due to infection) could also not participate, as well as patients with a previous pulmonary vein isolation (PVI), or intention to undergo PVI. The study was performed in concordance with the Declaration of Helsinki. The Institutional Review Board approved the protocol, and the study was registered at Clinicaltrials.gov (identifier NCT02726698). All centres approved the protocol and all patients gave written informed consent. Intended total follow-up duration is 2.5 years.
Publication 2020
Amiodarone Cardiac Resynchronization Therapy Defibrillators Diagnosis Ethics Committees, Research Fibrillation, Paroxysmal Atrial Heart Atrium Infection isolation Limb Prosthesis Pacemaker, Artificial Cardiac Patient Isolation Patients Pharmaceutical Preparations Precipitating Factors Pregnancy Transients Veins, Pulmonary
We used VDW files to obtain data on comorbidities and procedures from inpatient and ambulatory healthcare encounters using ICD-9 codes, lab test results, as well as ambulatory pharmacy databases and site-specific diabetes mellitus and cancer registries.
Prevalent HF was defined by any hospitalization or ambulatory HF diagnosis during the 5 years before the index date. During the 5 years before cohort entry and throughout the follow-up period, we also assessed patient records for diagnoses of acute myocardial infarction, unstable angina, coronary artery revascularization, stroke or transient ischemic attack, cerebrovascular disease, other thromboembolism, atrial fibrillation or flutter, ventricular fibrillation or tachycardia, mitral or aortic valvular heart disease, peripheral arterial disease, rheumatic heart disease, receipt of a pacemaker, receipt of cardiac resynchronization therapy, receipt of an implantable cardioverter defibrillator, dyslipidemia, hypertension, diabetes mellitus, hospitalized bleed, diagnosed dementia, diagnosed depression, chronic lung disease, chronic liver disease, mechanical fall, and systemic cancer using relevant ICD-9 codes and current procedural terminology codes that have been previously described.21 (link)At baseline and during the follow-up period, ambulatory systolic and diastolic blood pressure measurements were identified from VDW vital sign files, whereas information on serum low-density lipoprotien and high-density lipoprotein cholesterol measurements and blood hemoglobin levels were ascertained from site ambulatory lab databases.
Publication 2013
Angina, Unstable Artery, Coronary Atrial Fibrillation BLOOD Cardiac Resynchronization Therapy Cerebrovascular Accident Cerebrovascular Disorders Dementia Determination, Blood Pressure Diabetes Mellitus Diastole Disease, Chronic Dyslipidemias Hemoglobin Hepatobiliary Disorder High Blood Pressures High Density Lipoprotein Cholesterol Hospitalization Implantable Defibrillator Inpatient Liver Lung Lung Diseases Malignant Neoplasms Myocardial Infarction Pacemaker, Artificial Cardiac Patients Peripheral Vascular Diseases Rheumatic Heart Disease Serum Signs, Vital Systole Thromboembolism Transient Ischemic Attack Valve Disorder, Aortic Ventricular Fibrillation
The test case for benchmarking code scalability is derived from the heart of a cardiac resynchronization therapy candidate, the model development has been described previously (Niederer et al., 2010 (link)). Briefly, ventricular epicardium and left and right ventricular endocardium were segmented from MRI images acquired at end diastole using cmgui2. The segmented surfaces were fitted with cubic Hermite surfaces and converted into a volume mesh using CMISS3. The cubic Hermite mesh was converted to a binary image stack which was fed into the image-based mesh generation software Tarantula4 to generate a high resolution unstructured tetrahedral mesh. The resulting mesh consisted of 26 million nodes and 153 million elements with a mean edge length of 0.25 mm. To initialize the electrophysiological state of the ventricles, the isolated TNNP cell model was paced for 500 beats at 1 Hz to reach a limit cycle which was used then as the initial state in the whole ventricles. Left ventricular endocardial activation maps were used to fit monodomain conduction parameters giving values of σml = 0.035 and σmt = 0.023 Sm−1 in the fiber and transverse fiber direction, respectively. Activation at the septum was defined from left ventricular endocardial activation maps and right ventricular activation was approximated from the right ventricular activation in human hearts as described by Durrer et al. (1970 (link)). The stimulation current was applied at 50 μAmm−3 for 5 ms, first to the right ventricle activation region and then 33 ms later in the septum.
Publication 2011
Cardiac Resynchronization Therapy Cells Cuboid Bone Diastole Electric Conductivity Endocardium Epicardium Fibrosis Heart Heart Ventricle Homo sapiens Left Ventricles Microtubule-Associated Proteins Ventricles, Right
All patients who were scheduled for implant with a pacemaker between August of 2014 and October of 2015 and met all the inclusion criteria (age 18 years or older, ability to give informed consent and to operate the home monitor, life expectancy > 1 year) and none of the exclusion criteria (scheduled for implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy (CRT), participation in other trials) were invited to participate. A total of 76 patients were screened and 50 patients were included and randomized to either telemonitoring (TM, n = 25) or hospital monitoring (HM, n = 25). No changes to methods were performed after trial commencement.
Full text: Click here
Publication 2018
Cardiac Resynchronization Therapy Implantable Defibrillator Pacemaker, Artificial Cardiac Patients

Most recents protocols related to «Cardiac Resynchronization Therapy»

This was a cross-sectional study as well as a part of the Baduanjin-Eight-Silken-Movement with Self-efficacy Building for Patients with Chronic Heart Failure (BESMILE-HF) trial (NCT03180320, ClinicalTrials.gov, registration date: 08/06/2017) [6 (link)]. Patients with CHF were prospectively recruited between February 2019 and July 2022 if they fulfilled the following inclusion criteria: (1) ≥ 18 years of age; (2) met the diagnostic criteria for CHF [7 (link)]; (3) clinically stable, defined as symptoms/signs that remained generally unchanged for ≥ 1 month; (4) New York Heart Association class II or III; (5) used beta-blockers; and (6) provided informed consent [8 (link)].
The exclusion criteria were as follows: (1) patients with contraindications for exercise testing, namely, early phase after acute coronary syndrome (up to 6 weeks), life-threatening cardiac arrhythmias, acute heart failure (during the initial period of hemodynamic instability), uncontrolled hypertension (systolic blood pressure > 200 mmHg and/or diastolic blood pressure > 110 mmHg), advanced atrioventricular block, acute myocarditis and pericarditis, moderate to severe aortic valve/mitral stenosis, severe aortic valve/mitral regurgitation, severe hypertrophic obstructive cardiomyopathy, acute systemic illness, or intracardiac thrombus; (2) patients with serious acute or chronic diseases affecting major organs or with mental disorders; (3) patients with a history of cardiac surgery, cardiac resynchronization therapy, intracardiac defibrillation, or implantation of a combined device within the previous 3 months; (4) patients with a history of cardiac arrest within 1 year; (5) patients with a history of peripartum cardiomyopathy, hyperthyroid heart disease, or primary pulmonary hypertension; and (6) patients unable to perform a recumbent bicycle stress test (Fig. 1) [6 (link)].

Flow chart of this study

Eligible participants underwent clinical evaluation (including history of cardiac risk factors and medications), height and weight measurements, blood testing, and electrocardiography. They then underwent a cardiopulmonary exercise test (CPET) and transthoracic echocardiography assessment at rest on the same day (Fig. 2A, B). The BESMILE-HF study[6 (link)] was approved by the Ethics Committee of the Guangdong Provincial Hospital of Chinese Medicine (Approval No. B2016-202-01). All of the participants provided written informed consent.

Illustration of speckle-tracking echocardiography examination (A) and cardiopulmonary exercise testing (B). Strain analysis of the left atrium in the locally enlarged apical four-chamber view and the LA strain curve throughout the cardiac cycle (C). The curves of VO2 and VCO2 with time and work rate, respectively (D). LA, left atrial; VO2, oxygen uptake; VCO2, carbon dioxide uptake; VO2max/pre, ratio of maximum to predicted oxygen uptake, WR, work rate

Full text: Click here
Publication 2023
Acute Coronary Syndrome Adrenergic beta-Antagonists Aortic Valve Insufficiency Aortic Valve Stenosis Atrioventricular Block Atrium, Left Carbon dioxide Cardiac Arrest Cardiac Arrhythmia Cardiac Resynchronization Therapy Cardiomyopathies Chinese Diagnosis Disease, Chronic Echocardiography Electric Countershock Electrocardiography Ethics Committees, Clinical Exercise Tests Heart Heart Diseases Heart Failure Hemodynamics High Blood Pressures Hyperthyroidism Hypertrophic Obstructive Cardiomyopathy Idiopathic Pulmonary Arterial Hypertension Medical Devices Mental Disorders Movement Myocarditis Ovum Implantation Oxygen Patients Pericarditis Pharmaceutical Preparations Pressure, Diastolic Signs and Symptoms Silk Strains Surgical Procedure, Cardiac Systolic Pressure Thrombus
The data were extracted independently by two authors (Z.W., and W.Z.). Duplicates were removed first, and titles and abstracts were screened followed by full texts studies for potential eligibility.
From the retrieved studies, the following characteristics were extracted: first author, year of publication, inclusion period, study design, data source, device types, sample size, number of ITTVR and TMTVR patients, patient age and sex, European System for Cardiac Operative Risk Evaluation II (EuroSCORE II) score, proportion of functional TR, medical history of hypertension, diabetes mellitus, atrial fibrillation, permanent pacemaker (PPM)/implantable cardioverter defibrillator (ICD)/cardiac resynchronization therapy (CRT) implantation, follow-up time and number of aforementioned events.
Publication 2023
Atrial Fibrillation Cardiac Resynchronization Therapy Diabetes Mellitus Eligibility Determination Europeans Heart High Blood Pressures Implantable Defibrillator Medical Devices Ovum Implantation Pacemaker, Artificial Cardiac Patients
The study was designed, performed, and reported following the STROBE reporting guidelines and in accordance with the Helsinki Declaration.25 (link) It was performed in a 20-bed surgical ICU at Beijing Chaoyang Hospital from January 1, 2018, to December 31, 2021. We continuously screened postoperative adult patients who underwent general and thoracic surgery. Patients had multiple ICU admissions or were included only once. The exclusion criteria were age < 18 years; AF or flutter detected in preoperative examination or electrical monitoring during surgery; received amiodarone before operation; the presence of a cardiac implantable electronic device with a functioning atrial lead (pacemaker, implantable cardioverter defibrillator, or cardiac resynchronization device); underwent transplantation surgery; or none critical data (missing data of electrocardiogram [ECG], ultrasonic cardiogram, and baseline data before admission).
Publication 2023
Adult Amiodarone Cardiac Resynchronization Therapy Electricity Electrocardiogram Heart Heart Atrium Implantable Defibrillator Medical Devices Pacemaker, Artificial Cardiac Patients Thoracic Surgical Procedures Transplantation Ultrasonics
This was a retrospective observational cohort study of patients who received a newly implanted CIED or device exchange at Massachusetts General Hospital between January 2017 and December 2020. CIED was defined as any kind of pacemaker (single lead, 2 leads, and leadless), cardiac resynchronization pacemaker, implantable cardioverter‐defibrillator, and cardiac resynchronization therapy with an implantable defibrillator. Patients had to be >21 years of age.
Sociodemographic patient characteristics were obtained from the electronic medical record including age, sex, ancestry, preferred language, insurance type/primary payer, patient portal enrollment, and county‐code–linked median household income (MHI). MHI used in this study was paired to the primary patient residence and was acquired from the 2019 data from the US Census Bureau. Patients residing in the following New England states were included: Maine, Vermont, New Hampshire, Massachusetts, Connecticut, and Rhode Island. Patients who received an implantable loop recorder were excluded.
Publication 2023
Cardiac Resynchronization Therapy Households Implantable Defibrillator Medical Devices Pacemaker, Artificial Cardiac Patients

I. Heart failure caused by valvular disease, precordial disease, or pericardial disease.

II. Patients with tumors, severe endocrine system disease, psychiatric disease, severe primary disease of the hematopoietic system, uncontrollable malignant arrhythmias, second-degree type II or greater sinus or atrioventricular block without pacemaker protection, progressive exacerbation of acute coronary syndrome, uncontrolled hypertensive crisis, hypokalemia.

III. Patients planning to receive coronary revascularization therapy or cardiac resynchronization therapy within 1 month.

IV. Women who are pregnant or planning to become pregnant and women who are breastfeeding for a short period of time.

V. Allergic patients or those with known allergy to therapeutic drugs.

VI. Those who are undergoing other drug trials.

Full text: Click here
Publication 2023
Acute Coronary Syndrome Allergic Reaction Atrioventricular Block Cardiac Arrhythmia Cardiac Resynchronization Therapy Endocrine System Diseases Heart Heart Failure Hematopoietic System Mental Disorders Neoplasms Pacemaker, Artificial Cardiac Patients Pericardium Pharmaceutical Preparations Sinuses, Nasal Therapeutics Woman

Top products related to «Cardiac Resynchronization Therapy»

Sourced in United States, New Zealand
Cognis is a laboratory equipment product designed to perform advanced signal processing and waveform analysis. It is a versatile tool that captures, processes, and analyzes complex signals across various applications.
Sourced in United States
The LATITUDE Patient Management System is a medical device used to monitor and manage implanted cardiac devices, such as pacemakers and defibrillators. It enables remote communication between healthcare providers and patients with these implanted devices.
Sourced in Germany, Switzerland, United States, Japan, United Kingdom, Denmark, France, Poland
The Cobas e411 is a compact and fully automated immunoassay analyzer designed for clinical laboratory settings. It is capable of performing a wide range of immunoassay tests, including those for hormones, therapeutic drug monitoring, and infectious disease markers. The Cobas e411 is known for its reliability, ease of use, and efficient throughput.
Sourced in United States, United Kingdom, Denmark, Austria
Stata is a general-purpose statistical software package for data analysis, data management, and graphics. It provides a wide range of data manipulation, statistical, and graphical tools to help researchers and analysts effectively analyze and visualize data.
Sourced in Germany
Home Monitoring is a device that allows patients to transmit medical data from their homes to their healthcare providers. The device collects and transmits information about the patient's health status, enabling remote monitoring and management of their condition.
Sourced in Japan
The ECG monitor is a medical device used to record the electrical activity of the heart. It provides a real-time display of the heart's electrical signals, allowing healthcare professionals to monitor and analyze the heart's function.
Sourced in Netherlands, Germany, United States
The Intera is a lab equipment product by Philips. It is a diagnostic imaging device used for magnetic resonance imaging (MRI) procedures. The core function of the Intera is to generate high-quality images of the body's internal structures and organs to assist healthcare professionals in medical diagnosis and treatment planning.
Sourced in Germany, Japan, United States
Gadobutrol is a gadolinium-based contrast agent used in magnetic resonance imaging (MRI) procedures. It is a paramagnetic contrast agent that enhances the visibility of internal body structures during MRI scans.
Sourced in United States
The CareLink Network is a secure remote monitoring system that allows healthcare providers to access and review patient data from compatible medical devices. It facilitates the collection and transmission of patient data to healthcare providers for review and management of the patient's condition.
Sourced in United States
The Lumax is a cardiac diagnostic device manufactured by Biotronik. It is designed to monitor and record cardiac activity. The core function of the Lumax is to collect and analyze data related to the electrical activity of the heart.

More about "Cardiac Resynchronization Therapy"

Cardiac Resynchronization Therapy (CRT) is a cutting-edge treatment approach used to manage heart failure patients with electrical conduction delays.
This therapy involves implanting a specialized pacemaker device that coordinates the contractions of the heart's lower chambers (ventricles), improving the efficiency of the pumping action.
This can help alleviate symptoms, enhance quality of life, and reduce the risk of hospitalization for individuals with certain types of heart failure.
PubCompare.ai's innovative AI-driven platform empowers researchers to easily locate the best CRT research protocols from the literature, preprints, and patents, facilitating reproducibility and accuracy in their investigations.
This platform, which integrates seamlessly with tools like Cognis, LATITUDE Patient Management System, Cobas e411, Stata software, Home Monitoring, ECG monitor, Intera, Gadobutrol, CareLink Network, and Lumax, represents the future of protocol optimization.
By leveraging the power of intelligent comparisons, researchers can enhance the quality and reliability of their CRT-related studies, ultimately leading to improved patient outcomes.
Experience the future of protocol optimization today with PubCompare.ai's cutting-edge tools and discover the full potential of Cardiac Resynchronization Therapy (CRT).